News
Public · Published
Guggenheim maintains AbbVie at Buy, raises price target to $322 from $288
Guggenheim kept its Buy rating on AbbVie and raised its price target to $322 from $288, an 11.8% increase. The new target implies 9.2% upside from AbbVie's Oct. 30 closing price of $294.89. Five recent analyst targets listed range from $294 to $340.
Published:
Updated:
What happened
Guggenheim kept its Buy rating on AbbVie and raised its price target to $322 from $288, an 11.8% increase. The new target implies 9.2% upside from AbbVie's Oct. 30 closing price of $294.89. Five recent analyst targets listed range from $294 to $340.
Confirmed
Global impact / market context
A higher target signals that Guggenheim sees more potential value in AbbVie shares, but it is an analyst estimate, not a promised return. If investors act on the view, increased demand could support the share price; the article gives no evidence of an actual market reaction.
Analyst inference
Recent opinions are mixed: the listed targets span $294 to $340, while ratings include Buy, Overweight, Outperform, and Neutral. The range shows analysts do not share one valuation, and the $322 target sits within that spread rather than establishing a consensus.
Confirmed
What to watch
- Compare upcoming analyst targets and ratings with the current $294–$340 range to see whether views on AbbVie are converging or diverging. Analyst inference
- Check whether subsequent company results or outlook updates support assumptions behind higher targets; this article provides no operating results or reasons for Guggenheim's change. Analyst inference
- Track AbbVie's share price against Guggenheim's $322 target and its stated 9.2% implied upside from the Oct. 30 close. Analyst inference
Evidence
- Original source link unavailable